• Publications
  • Influence
Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys.
OBJECTIVE Generalized anxiety disorder might be better conceptualized as a prodrome, residual, or severity marker of major depression or other comorbid disorders than as an independent diagnosis. TheExpand
  • 435
  • 32
  • PDF
Characteristics and motives of college students who engage in nonmedical use of methylphenidate.
Methylphenidate (MPH) has a long history of being an effective medication for attention deficit/hyperactivity disorder (ADHD). Recently, the nonmedical use of MPH has increased, particularly amongExpand
  • 145
  • 25
Economic costs of anxiety disorders.
Anxiety disorders are estimated to affect 26.9 million individuals in the United States at some point during their lives. This study used the human capital approach to estimate the direct andExpand
  • 277
  • 24
Confronting Drunk Driving: Social Policy for Saving Lives
In this important new book, H. Laurence Ross reviews the history of the problem of drunk driving and presents a critique of current efforts to make the punishments for drunk driving even more severe.Expand
  • 51
  • 12
Nonmedical Prescription Stimulant Use Among College Students: Why We Need to Do Something and What We Need to Do
ABSTRACT This article summarizes recent research findings on nonmedical use of prescription stimulants and outlines a multi-pronged strategic approach for responding to this unique problem amongExpand
  • 138
  • 11
  • PDF
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment.
Following promising preliminary evidence, the benzodiazepine-derivative alprazolam was studied in a large, placebo-controlled, eight-week, flexible-dose trial in patients with agoraphobia with panicExpand
  • 465
  • 9
How are addicted physicians treated? A national survey of Physician Health Programs.
INTRODUCTION Physicians with substance use disorders receive care that is qualitatively different from and reputedly more effective than that offered to the general population, yet there has been noExpand
  • 129
  • 9
  • PDF
Economic costs of obsessive-compulsive disorder.
Obsessive-compulsive disorder (OCD), classified as a severe mental illness by the National Advisory Mental Health Council, affects 2.1% of the population annually, as shown by the EpidemiologicalExpand
  • 128
  • 8
Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
BACKGROUND The objective of this randomized, double-blind study was to compare the efficacy and safety of venlafaxine extended release (XR) and buspirone in outpatients with generalized anxietyExpand
  • 246
  • 7
Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States
Objective To evaluate the effectiveness of US state physician health programmes in treating physicians with substance use disorders. Design Five year, longitudinal, cohort study. Setting PurposiveExpand
  • 149
  • 6